Jiangsu #Hengrui Pharma's oral thrombopoietin (#TPO) receptor agonist #hetrombopag has been approved in #China to treat low platelet counts (thrombocytopenia) caused by #chemotherapy for #solidtumours.

buff.ly/acx4yvZ